- Case report
- Open Access
- Open Peer Review
Brain localization of Kaposi’s sarcoma in a patient treated by combination antiretroviral therapy
© Baldini et al.; licensee BioMed Central Ltd. 2013
- Received: 3 September 2013
- Accepted: 16 December 2013
- Published: 21 December 2013
Central nervous system is a very rare site of Kaposi’s sarcoma in acquired immunodeficiency syndrome. Kaposi’s sarcoma, a neoplasm of endothelial origin, occurs mainly in the skin, but can involve many tissues, especially in patients with a poor immunity. Combination antiretroviral therapy, highly active against human immunodeficiency virus type-1, has caused a dramatic reduction of cutaneous and visceral involvements. No report of central nervous system localization of Kaposi’s sarcoma is described since the introduction of combination antiretroviral therapy in the late 90’s.
A 42 year-old Caucasian man affected by human immunodeficiency virus type-1 infection treated with combination antiretroviral therapy and showing relatively preserved immunity with low viral load presented gingival squamous cell carcinoma and visceral (lungs and lymph nodes) Kaposi’s sarcoma. Chemotherapy and radiotherapy were performed with improvement of both neoplasms. Afterwards, a magnetic resonance imaging showed focal lesions of the brain. Despite new chemotherapy and radiotherapy the patient died. Histology after autopsy revealed brain lesions due to Kaposi’s sarcoma with the detection of Human Herpesvirus 8 on tissue samples.
This is the first report in the combination antiretroviral therapy era of a very rare complication of Kaposi’s sarcoma, such as that of brain localization, in a patient with a relatively good control of human immunodeficiency virus infection. Therefore, Kaposi’s sarcoma should be considered in differential diagnosis with other intracranial mass lesions that can occur in human immunodeficiency virus infected-patients focusing the issue of appropriate treatment for central nervous system involvement.
- Kaposi’s sarcoma
- Combination antiretroviral therapy
- Central nervous system
Since the first appearance, acquired immunodeficiency syndrome (AIDS) and Kaposi’s sarcoma (KS), a multicentric angioproliferative spindle cell tumor of endothelial origin, were associated . KS can occur in many tissues, mainly in the skin, but also in visceral sites involving various organs like the gastrointestinal tract, the lungs, the lymph nodes, and the bone. For mucocutaneous KS an inspective, presumptive diagnosis is accepted . DNA sequences of a new γ-herpesvirus were shown to be invariably present in KS lesions, but not in unaffected skin or in several other diseased tissues; hence the new virus was named KS-associated herpesvirus . This virus belongs to the herpesviridae family, and is also taxonomically classified as Human Herpesvirus 8 (HHV8). The causal association between HHV8 and KS has been subsequently proven by unequivocal evidence, including the overlapping global patterns of disease incidence and viral seroprevalence  and gave a support for the diagnosis. However, for diagnosis of certain localizations, other than mucocutaneous forms like lymph nodes and bone, histological examination remains necessary, because a differential diagnosis between KS and other diseases is required. Currently KS continues to represent one of the most relevant cause of AIDS-defining events, although less frequently since the introduction of combination antiretroviral therapy (cART), which caused a dramatic reduction of cutaneous manifestation and visceral involvements . Central nervous system (CNS) is a very rare site of KS, both in the human immunodeficiency virus type 1 (HIV-1)  and in the general population setting . Isolated histological cases of brain KS in HIV-infected patients were reported at the beginning of the AIDS era and before the introduction of cART. Some were fully characterized cases, others were found in CNS diseases studies or in retrospective autoptic series of HIV-infected patients [8–13]. Up to now, no report of brain localization is described in cART era.
We here describe the case of a HIV-1-infected patient with KS involvement of the brain, focusing on histopathological, virological and radiological features.
A 42 year-old Italian man diagnosed with HIV-1 infection since 1993, was admitted at our hospital in April 2011 complaining about an acute pain at the right zygoma. At medical examination he had a vegetated lesion of the gingiva, arising from the superior maxilla, and an enlargement of right supraclavear lymph nodes. Examination of the other organs was normal. CD4+ cell count was 243/mm3 and HIV-1 RNA in plasma was 68 copies/mL.
At clinical history, cutaneous and pulmonary KS had been diagnosed in 1993 and at that time successfully treated with interferon alfa and chemotherapy. CD4+ cell count nadir was 52/mm3 and hepatitis C virus coinfection was documented. In recent years, only occasional bacterial pneumonia had occurred. cART was started in 1997 and changed to various regimens up to 2008, since when the current cART based on co-formulated tenofovir-emtricitabine, raltegravir, and darunavir/ritonavir had been prescribed. This salvage therapy was chosen after HIV genotypic resistance test that documented mutation associated with multidrug resistance. CD4+ cell count had stably risen above 200/mm3 since December 2008 and HIV-1 RNA level was constantly below 500 copies/mL since October 2009.
During hospitalization a total body computerized tomography (CT) showed multiple nodular lesions in both lungs, minimal right pneumothorax, pathological soft tissue in the right maxillar sinus, and enlargement of supraclavear lymph nodes. CT scan of the brain was normal. Biopsy specimen from gingival lesion revealed squamous cell carcinoma, while tissue taken from supraclavear lymph node showed histological features of KS. HHV8-DNA by polymerase chain reaction (PCR) was negative on blood. Four cycles of chemotherapy using liposomial doxorubicin (20 mg/m2) were performed, and after only two cycles an improvement of CT findings was documented. Then, ten sessions of radiotherapy on maxillofacial site for carcinoma were performed (total dose 30 Gy).
This case report describes an HIV-1-infected patient presenting brain localization of KS, despite previously administered chemoterapy and cART treatment. Disease localization was documented by accurate histological, virological and radiological examination with MRI and DWI. At first evaluation of the patient, absence of cutaneous neoplastic lesions, immunological status with CD4+ cell count stably above 200/mm3, HIV-1 RNA of 68 copies/mL, negative HHV8 PCR in the peripheral blood, and diagnosis of concurrent gingival carcinoma made the diagnosis of KS unlikely.
In the pre-cART era, HIV-1-infected patients with KS typically had a low CD4 cell count and a high HIV viral load. Since the introduction of cART, the incidence of KS has decreased  and survival improved [15, 16]. Further, it is well documented that cART, especially HIV protease inhibitors, can improve KS lesions with or without use of liposomal anthracycline [15, 17]. However, unusual cases of cutaneous HIV-associated KS occurring even during stable immunologic rescue and HIV-RNA suppression in plasma are reported [18, 19].
Our patient was cART-experienced, with genotypic multi-drug resistance in HIV. Despite the high-level resistance, re-optimized cART allowed to obtain stable low-level viremia in plasma close to 50 copies/mL cut-off. Biopsy of the lymph node revealed histologic KS and allowed starting chemotherapy with improvement of visceral lesions. At the onset of neurological symptoms, brain mass lesions at MRI were detected. Radiologic features of intracranial KS have only rarely been described; intracranial masses of the patient had a vascular component, and appeared as a inhomogeneous mass with hyperintense signal on T1- and on T2-weighted images, with surrounding edema, minimal mass effect and with faintly ring enhancement. The hyperintensity on T1-weighted images probably was due to abnormally increased blood vessels with slow intra-lesional flow. The low ADC value of KS lesions might be due to its histological architecture made of high tumor cellularity and relatively large vascular spaces. Although no studies have elucidated the direct relationship between blood flow velocity and vascular spaces size we hypothesise that blood velocity in KS lesions is low because of the large vascular spaces, and that this may determine the increased signal strengths and lower ADCs on DWI. FDG-PET of the body only showed the suspicion of neoplastic disease in various tissues, but FDG-PET of the brain unfortunately was not performed. Only autopsy specimens allowed obtaining the diagnosis of KS, that was confirmed by the detection of HHV8-DNA in the brain tissues. In HIV-infected patients, differential diagnosis of mass lesions is required. Mass algorithms in the pre-cART era were well defined, but in the cART era, when the epidemiology of opportunistic infections changed, are lacking. Brain biopsy, if feasible, is no longer mandatory for the diagnosis of mass lesions in HIV-patients , however histological examination in some cases is still the only way to obtain a definitive diagnosis.
Only few histologically proven cases of KS metastatic to the brain in HIV-1 patients have been described: up to now Gorin et al. reported two cases at the beginning of the AIDS era , and Buttner et al. described in 1997 a patient who had never taken cART . Two more cases were published by Levy et al. and one was observed by Post et al. in CNS diseases studies performed in the 80’s . In a morphological analysis of brains from 100 AIDS patients observed in the course of 1987–1995 years, Mossakowski et al. found one case of cerebral KS , so did Jellinger et al. in a retrospective study on 450 consecutive autoptical AIDS cases between 1984 and 1999, only in the cohort of 1984–1992 . Most of these cases were observed in advanced patients with other concomitant AIDS-related events and none occurred during antiretroviral treatment. Moreover, in our patient cART was mainly effective, with low plasma viral copies and partial immune recovery.
The cause of brain involvement in this patient despite an initial improvement of visceral lesions with the appropriate treatment , is difficult to explain. Furthermore, it is well documented that positive HHV8 DNA on peripheral blood or a CD4 level below 200/mm3 are risk factors of poor evolution of KS , but the patient had a stable immunity and a persistent negative blood HHV8 DNA. Despite incomplete suppression of HIV-1 replication, cART was effective to prevent the development of opportunistic infections in all the clinical history of the patient. We know that HIV-1 plays a role on the KS diffusion through the production and the release of the HIV-1 Tat protein, a KS progression factor, and that cART has a documented direct anti-angiogenetic effect [23, 24]. In this case, independently of the CD4 cell count, the incomplete suppression of HIV-1 could have enhanced the diffusion of KS, producing an increased release of the HIV-1 Tat protein.
This case describes a rare complication of KS, never reported in the cART era, and raises a question about the diagnosis and the treatment suggesting that KS should be considered for the differential diagnosis with other intracranial mass lesions that can occur in HIV patients and focusing on the problem of appropriate treatment for CNS involvement.
The case described was approved by an internal revision group at the Direction of Clinical Department.
Written informed consent was obtained from the wife of the patient for publication of this case report and any accompanying images. A copy of the consent form is available for review by the Editor of this journal.
We thank S. Paradiso and V. Scopece for their expert technical assistance; and Dr. R. Mancini and M. D’Adduogo for help in bibliographic research.
- Friedman-Kien AE, Laubenstein LJ, Rubinstein P, Buimovici-Klein E, Marmor M, Stahl R, Spigland I, Kim KS, Zolla-Pazner S: Disseminated Kaposi’s sarcoma in homosexual men. Ann Intern Med. 1982, 96: 693-700. 10.7326/0003-4819-96-6-693.View ArticlePubMedGoogle Scholar
- Centers for Disease Control and Prevention (CDC): 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992, 41: 1-19.Google Scholar
- Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994, 266: 1865-1869. 10.1126/science.7997879.View ArticlePubMedGoogle Scholar
- Mesri EA, Cesarman E, Boshoff C: Kaposi’s sarcoma and its associated herpesvirus. Nat Rev Cancer. 2010, 10: 707-719. 10.1038/nrc2888.View ArticlePubMedPubMed CentralGoogle Scholar
- Mocroft A, Kirk O, Clumeck N, Gargalianos-Kakolyris P, Trocha H, Chentsova N, Antunes F, Stellbrink HJ, Phillips AN, Lundgren JD: The changing pattern of Kaposi sarcoma in patients with HIV, 1994–2003: the EuroSIDA Study. Cancer. 2004, 100: 2644-2654. 10.1002/cncr.20309.View ArticlePubMedGoogle Scholar
- Pantanowitz L, Dezube BJ: Kaposi sarcoma in unusual locations. BMC Cancer. 2008, 8: 190-10.1186/1471-2407-8-190.View ArticlePubMedPubMed CentralGoogle Scholar
- Bahat E, Akman S, Karpuzoglu G, Aktan S, Ucar T, Arslan AG, Nenonen N, Gur Guven A, Karpuzoglu T: Visceral Kaposi’s sarcoma with intracranial metastasis: A rare complication of renal transplantation. Pediatr Transplantation. 2002, 6: 505-508. 10.1034/j.1399-3046.2002.00023.x.View ArticleGoogle Scholar
- Gorin FA, Bale JF, Halks-Miller M, Schwartz MA: Kaposi’s sarcoma metastatic to the CNS. Arch Neurol. 1985, 42: 162-165. 10.1001/archneur.1985.04060020076020.View ArticlePubMedGoogle Scholar
- Buttner A, Marquart KH, Mehraein P, Weis S: Kaposi’s sarcoma in the cerebellum of patient with AIDS. Clin Neuropathol. 1997, 16: 185-189.PubMedGoogle Scholar
- Levy RM, Pons VG, Rosenblum ML: Central nervous system mass lesions in the acquired immunodeficiency syndrome (AIDS). J Neurosurg. 1984, 61: 9-16. 10.3171/jns.1984.61.1.0009.View ArticlePubMedGoogle Scholar
- Post MJ, Sheldon JJ, Hensley GT, Soila K, Tobias JA, Chan JC, Quencer RM, Moskowitz LB: Central nervous system disease in acquired immunodeficiency syndrome: prospective correlation using CT, MR imaging, and pathologic studies. Radiology. 1986, 158: 141-148.View ArticlePubMedGoogle Scholar
- Mossakowski MJ, Zelman IB: Neuropathological syndromes in the course of full blown acquired immune deficiency syndrome (AIDS) in adults in Poland (1987–1995). Folia Neuropathol. 1997, 35: 133-143.PubMedGoogle Scholar
- Jellinger KA, Setinek U, Drlicek M, Böhm G, Steurer A, Lintner F: Neuropathology and general autopsy findings in AIDS during the last 15 years. Acta Neuropathol. 2000, 100: 213-220. 10.1007/s004010000245.View ArticlePubMedGoogle Scholar
- Lallemand F, Desire N, Rozenbaum W, Nicolas JC, Marechal V: Quantitative analysis of human herpes 8 viral load using a real-time PCR assay. J Clin Microbiol. 2000, 38: 1404-1408.PubMedPubMed CentralGoogle Scholar
- Holkova B, Takeshita K, Cheng DM, Volm M, Wasserheit C, Demopoulos R, Chanan-Khan A: Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi’s sarcoma treated with chemotherapy. J Clin Oncol. 2001, 19: 3848-3851.PubMedGoogle Scholar
- Martinez V, Caumes E, Gambotti L, Ittah H, Morini JP, Deleuze J, Gorin I, Katlama C, Bricaire F, Dupin N: Remission from Kaposi’s sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. Br J Cancer. 2006, 94: 1000-1006. 10.1038/sj.bjc.6603056.View ArticlePubMedPubMed CentralGoogle Scholar
- Nasti G, Martellotta F, Berretta M, Mena M, Fasan M, Di Perri G, Talamini R, Pagano G, Montroni M, Cinelli R, Vaccher E, D’Arminio Monforte A, Tirelli U: Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with Acquired Immunodeficiency Syndrome–Related Kaposi sarcoma. Cancer. 2003, 98: 2440-2446. 10.1002/cncr.11816.View ArticlePubMedGoogle Scholar
- Maurer T, Ponte M, Leslie K: HIV-associated Kaposi’s sarcoma with a high CD4 count and a low viral load. N Engl J Med. 2007, 357: 1352-1353. 10.1056/NEJMc070508.View ArticlePubMedGoogle Scholar
- Krown SE, Lee JY, Dittmer DP: More on HIV-associated Kaposi’s sarcoma. N Engl J Med. 2008, 358: 535-536.View ArticlePubMedPubMed CentralGoogle Scholar
- Antinori A, Ammassari A, Luzzati R, Castagna A, Maserati R, Rizzardini G, Ridolfo A, Fasan M, Vaccher E, Landonio G, Scerrati M, Rocca A, Butti G, Nicolato A, Lazzarin A, Tirelli U: Role of brain biopsy in the management of focal brain lesions in HIV-infected patients. Gruppo Italiano Cooperativo AIDS & Tumori. Neurology. 2000, 54: 993-997. 10.1212/WNL.54.4.993.View ArticlePubMedGoogle Scholar
- Bower M, Collins S, Cottrill C, Cwynarski K, Montoto S, Nelson M, Nwokolo N, Powles T, Stebbing J, Wales N, Webb A, AIDS Malignancy Subcommittee: British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med. 2008, 9: 336-388. 10.1111/j.1468-1293.2008.00608.x.View ArticlePubMedGoogle Scholar
- El Amari EB, Toutous-Trellu L, Gayet-Ageron A, Baumann M, Cathomas G, Steffen I, Erb P, Mueller NJ, Furrer H, Cavassini M, Vernazza P, Hirsch HH, Bernasconi E, Hirschel B, Swiss HIV Cohort Study: Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era. AIDS. 2008, 22: 1019-1028. 10.1097/QAD.0b013e3282fc9c03.View ArticlePubMedGoogle Scholar
- Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, Palladino C, Leone P, Bugarini R, Malavasi L, Cafaro A, Falchi M, Valdembri D, Rezza G, Bussolino F, Monini P, Ensoli B: HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med. 2002, 8: 225-232. 10.1038/nm0302-225.View ArticlePubMedGoogle Scholar
- Pati S, Pelser CB, Dufraine J, Bryant JL, Reitz MS, Weichold FF: Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood. 2002, 99: 3771-3779. 10.1182/blood.V99.10.3771.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/13/600/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.